

## Attention New Product: Flebogamma

Due to the voluntary withdrawal of Octagam, a replacement product has had to be implemented at short notice.

Flebogamma is approved by the TGA and has similar actions to Octagam. There are some important differences:

- Flebogamma is stabilised with sorbitol rather than maltose;
- Therefore Flebogamma is contraindicated in inherited fructose intolerance;
- Flebogamma does not interfere with BSL monitoring as does Octagam;
- Flebogamma has a different rate of infusion.

Flebogamma should be administered in accordance with the hospital IVIg infusion policy; however the infusion is commenced at a different rate. The following infusion rates are recommended for infusion of Flebogamma:

Infusion Rates (mls/hr)								
Infusion time	Rate of infusion (mls/kg/hr)	Weight						
		40	50	60	70	80	90	100
<b>First 30mins*</b>	1	40	50	60	70	80	90	100
<b>30-45 mins</b>	2	80	100	120	140	160	180	200
<b>45-60mins</b>	3	120	150	180	210	240	270	300
<b>60-75 mins</b>	4	160	200	240	280	320	360	400
<b>75-90 mins</b>	5	200	250	300	350	400	450	500
<b>After 90 mins*</b>	6	240	300	360	420	480	540	600

- Note that the time on the **first increment is 30 minutes rather than 15 minutes** as noted in the current IVIg policy, but that the maximum rate of infusion is greater

Dr Philip Crispin

Clinical Haematologist, ACT Pathology & Canberra Hospital

Lecturer, Australian National University Medical School

Ph 02 5124 3964

Fax 02 5124 2892

Phone 02 5124 2932 Fax 02 5124 2815

actpathology@act.gov.au

www.health.act.gov.au/services/act-pathology

Gilmore Crescent Garran ACT 2605 PO Box 11 Woden ACT 2606